Description
Pharma Clinical Trials & R&D Stage-Gate Valuation Model (2027 Edition)
Engineered for Biotech CEOs, Pharma Chief Medical Officers, Life Sciences PE Sponsors, and Licensing Heads. Calculates risk-adjusted Net Present Value (rNPV), clinical phase transition probabilities, and milestone licensing waterfalls.
Strategic Problems Solved & Enterprise Risks Prevented
- Prevents Capital Over-Allocation: Eliminates static DCF errors by weighting cash flows by empirical clinical success rates.
- Structures Licensing Milestones: Balances upfront payments, developmental milestones, and tiered net sales royalties.
- Accelerates Partnering: Formulates institutional 40-slide due diligence pack for big pharma partnering.
Exact Turnkey Artifacts Included in Download (.ZIP)
High-Resolution Excel Worksheet Structure
Technical Integrity & Global Regulatory Compliance
Software Compatibility
- Microsoft Excel 365, 2021, 2019, 2016 (PC & Mac)
- Google Sheets Native Import Verified
- Zero circular references; 100% unlocked formula integrity
- Firewall-safe: 0 VBA/macros to prevent corporate proxy quarantine
Regulatory Directives Aligned
- ICH E6 (R2/R3) Good Clinical Practice (GCP) Guidelines
- FDA 21 CFR Part 312 (IND) and Part 314 (NDA) Regulations
- EMA Clinical Trial Regulation (EU) No 536/2014
90-Day Implementation & Board Cadence
Multi-Seat Corporate Licensing Structure





Reviews
There are no reviews yet.